An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of a new article in the prestigious international journal “Cancers.” The article titled “Antigen MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance” describes the anti-tumor efficacy obtained in preclinical studies related to our new drug BGA002 for the treatment of small cell lung cancer. Lung cancer is the leading cause of cancer death in humans, and small cell lung cancer is the most aggressive and deadly form, and the most associated with smoking.
The publication is titled “Antigen MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance” (Bortolotti et. Al, Cancers, Feb. 2023).
link to article:
https://pubmed.ncbi.nlm.nih.gov/36765949/
Download article:
